Category: The Business of Cannabis

  • Regulatory chaos threatens US hemp industry

    Regulatory chaos threatens US hemp industry

    The U.S. hemp-derived cannabinoid market has swelled in total value, but the industry continues to face serious threats from a messy patchwork of state bans and regulations that are stunting growth and pushing production overseas, according to a leading cannabis economist.

    “All this hysteria over cannabinoids is having a profound effect on the fiber and grain environment,” said Beau Whitney, founder of Whitney Economics, told Green Market Report in an interview.

    Whitney’s analysis shows the hemp market, including CBD, THC, CBN, CBG and related compounds, has grown into a robust industry that now rivals legal marijuana markets. Two years ago, his firm calculated the total market for hemp-derived cannabinoids ranged from $21.3 billion to $35.8 billion, with a midpoint of $28.4 billion.

    Of that total market, Whitney noted that “about $21 billion was available on the legal side and then about $7 billion was on the illicit side.”

    Recent surveys conducted by Whitney in states, including Arizona, Illinois, Tennessee and Texas, validated these projections. “In states where I could get data and states that allowed for the sales, that’s where (the data is) really solid,” Whitney said. “They’re being confirmed as being conservative.”

    While it isn’t an apples-to-apples comparison, since Whitney’s measuring total market potential for hemp against only legal sales in the marijuana world, the economist said it’s becoming nearly impossible to measure legal hemp sales accurately as state regulations constantly shift.

    “Every time I turn around, a different state has a different proposal to ban all of this,” Whitney said.

    As a result, Whitney’s firm focuses on measuring total market potential rather than solely legal sales. Still, he sees potential growth beyond current projections, especially with hemp-derived cannabis beverages making a splashy entrance to the market.

    “Hemp-derived cannabis beverages, Delta-9 beverages, are coming on in a big way,” he said, noting these products are breaking out of traditional CBD shops and into “bars, liquor stores, restaurants and grocery stores.”

    According to Whitney, legislative approaches to hemp cannabinoids have had unintended consequences across the broader hemp industry. The confusion also affects hemp fiber and grain sectors that have nothing to do with intoxicating products.

    “Banks are debanking hemp fiber and hemp grain companies,” Whitney claimed. “Investors are pulling back on investment into the infrastructure.”

    Whitney calculated that “the lost economic potential because of these legislatures was between $20 (billion) and $25 billion dollars.” He added that he’s “taken (his) acreage forecast through 2030 down by over 4 million acres.”

    Whitney estimated “an impact to farmers of between $1 (billion) and $3.5 billion in revenue” in lost opportunities.

    Licensed hemp acreage plummeted from 525,000 acres in 2019 to just 30,000 acres last year. That decline means there isn’t enough domestic acreage to support the hemp cannabinoid industry, potentially pushing manufacturing overseas.

    “It’s driving manufacturers to China and to South America and Canada and anywhere else that can get CBD or CBD biomass,” Whitney said, which creates additional public safety risks as “Chinese CBD is laden with heavy metals.”

    He said that the irony is that policies ostensibly designed to protect public safety might actually be increasing risks. “The whole legislative goal of having increased public safety … all their policies are running against that, and they’re actually increasing the public safety risk rather than decreasing it.”

    Whitney has long advocated for product-level regulation rather than wholesale bans, suggesting age restrictions, testing requirements and proper labeling would be sufficient, “if it’s intoxicating.”

    “That’s all you need to do,” he said.

    Additionally, current regulatory approaches, he argued, are creating a false binary.

    “The dispensary model for marijuana is failed. It’s an abject failure because it’s limiting people’s access,” he said. “Not everybody wants to go in there.”

    Whitney also noted that declining commodity prices for corn, wheat, soybeans and other staple crops have driven farmers to seek higher-revenue alternatives. Hemp represents not only potential increased revenue per acre but also agricultural benefits – if the industry is actually allowed to develop.

    “Hemp is a great rotational crop because it helps with the soil, it restores certain aspects of the soil, and it takes impurities out of the soil,” Whitney explained. He added that using hemp in rotation can increase output for subsequent soybean crops “on a significant per bushel level.”

    Despite the challenges, Whitney still forecasts potential growth, projecting “a million acres in 2030, which is twice the size of it at its peak.”

    Many have attributed much of the regulatory confusion to federal inaction, particularly from the FDA, which has taken a hands-off approach and created much of the uncertainty. Whitney expressed hope that the upcoming farm bill might provide greater clarity, though he noted the legislation “has been pushed out a number of times.”

    The post Regulatory chaos threatens US hemp industry appeared first on Green Market Report.

  • Report: California regulators suspend cannabis lab’s business license for questionable test results

    Report: California regulators suspend cannabis lab’s business license for questionable test results

    California marijuana testing facility BelCosta Labs in Long Beach lost its business permit for allegedly inflating THC potency results for clients and other infractions, MJBizDaily reported Thursday, citing an April 10 letter from state regulators to the lab which said its permit was suspended “effective immediately.”

    The California Department of Cannabis Control also accused the lab of clearing marijuana products for sale that had failed contamination tests and were a potential threat to consumers.

    A spokesman for the lab, however, told MJBizDaily that the company believed it “was doing everything right” and obeying all state cannabis testing regulations.

    “We also don’t believe that we were anything close to a public safety or health concern,” BelCosta Vice President Nate Winokur told MJBizDaily.

    On Thursday, the DCC’s license database listed the lab’s permit as “suspended.” The license is set to expire April 30.

    It’s also not clear from the DCC letter if BelCosta has any immediate remedy to restart operations. CEO Myron Ronay indicated the lab may wind up suing the state if its permit is not restored.

    “If we cannot come to an agreement that salvages the business we have built over the last 8+ years we will be forced to resort to the court system,” Ronay wrote in an email to MJBizDaily.

    BelCosta executives also took to YouTube to publicly refute the DCC charges in the suspension letter and proclaimed that any issues were innocent mistakes, not nefarious rulebreaking. Winokur also suggested to MJBizDaily that his company may have been “singled out” by regulators for some reason.

    The post Report: California regulators suspend cannabis lab’s business license for questionable test results appeared first on Green Market Report.

  • Fluent posts $40M loss for 2024 despite New York entry, other expansion efforts

    Fluent posts $40M loss for 2024 despite New York entry, other expansion efforts

    Florida-based Fluent Corp. (CSE: FNT.U) (OTCQB: CNTMF) posted a $40.3 million net loss for the 2024 calendar year against $103.5 million in net revenues, the company reported on Thursday after U.S. markets closed.

    The annual loss was up 78% year-over-year from the $22.7 million net loss reported in 2023, which CEO Robert Beasley didn’t bother addressing in a press release.

    Rather, Beasley said the company is “positioning ourselves for continued success in the year ahead,” with the acquisition of RIV Capital in New York last year, followed by a rebranding from Cansortium to Fluent Corp., the launch of several new product lines and other expansion efforts that he said are already bearing fruit.

    Beasley also denied that the failure of recreational marijuana legalization at the ballot box last fall in Florida had a significant impact on the company’s business plans, but admitted the company’s been “somewhat impacted by broader industry dynamics.”

    “Many in the sector had prepared extensively for the amendment’s passage, and its delay has created market challenges, such as oversupply, heightened competition and increased product discounting,” Beasley said.

    For the fourth quarter, which ended on Dec.31, 2024, Fluent reported a year-over-year revenue downturn to $24.9 million from $25.5 million. For the full year, however, revenues were up 6.4% to $103.6 million from $97.3 million.

    In the final quarter of the year, Fluent also reported an impairment of intangible assets of $64.3 million, which it said was related to a license in Florida and “reduces the carrying value of the Company’s intangible assets on its consolidated statements of financial position to $37.6 million.”

    Fluent currently operates 42 dispensaries in Florida, New York, Pennsylvania and Texas, and said it expects to open at least three more in 2025. The company also expects to finish construction at a new cannabis cultivation facility in Tampa Bay by the end of the second quarter, which will add another 7,000 square feet of canopy to its production capacity.

    The company recently refinanced a $71 million loan from Chicago Atlantic that had been set to mature in May and inked a new $96.5 million credit line with the firm.

    At the end of December, Fluent had $61.4 million in total assets, including $40.1 million in cash, against $215.9 million in total liabilities.

    The post Fluent posts $40M loss for 2024 despite New York entry, other expansion efforts appeared first on Green Market Report.

  • STATES Act reintroduced in Congress with bipartisan support

    STATES Act reintroduced in Congress with bipartisan support

    A small bipartisan group of U.S. House of Representatives members on Thursday reintroduced the long-stalled STATES Act, a pro-marijuana bill that would both nullify the hated 280E tax provision for cannabis companies and also exempt states that have legalized marijuana from federal interference.

    The bill, this time called the STATES 2.0 Act, was introduced by U.S. Reps. Dave Joyce (R-OH), Dina Titus (D-NV) and Max Miller (R-OH). Joyce also introduced a separate bill co-sponsored by House Minority Leader Hakeem Jeffries (D-NY) dubbed the PREPARE Act, which is designed to pave the way for federal marijuana legalization.

    The first bill’s full name is the Strengthening the Tenth Amendment Through Entrusting States (STATES) 2.0 Act. If approved by both chambers and President Donald Trump, it would effectively remove states that have legalized marijuana from the jurisdiction of the federal Controlled Substances Act, reconciling legal tension between federal cannabis prohibition and state marijuana legality.

    The bill would also nullify the 280E provision of the federal tax code for licensed cannabis companies in states with legalized marijuana markets, thereby allowing the industry to claim standard business tax deductions and saving companies billions of dollars in taxes per year.

    Under the legislation, federal regulation of the national cannabis trade would fall to the Alcohol and Tobacco Tax and Trade Bureau and the Food and Drug Administration, meaning there would likely be a new federal regulatory framework for businesses that would apply to every state and U.S. territory that has legalized cannabis.

    “We can all agree that the current federal approach to cannabis policy is not working. As President Trump has acknowledged, the existing policy has caused unnecessary harm and squandered taxpayer dollars by diverting law enforcement resources from combatting violent crimes,” Joyce, the co-chair of the Congressional Cannabis Caucus, said in a press release. “The STATES 2.0 Act remedies this issue by bridging the gap between federal and state policy to create a more logical approach to cannabis regulation that allows each state to put the policies in place that work best for their communities.”

    Titus, the other co-chair of the Cannabis Caucus, said the STATES Act “ensures the federal government does not interfere with states or tribes that have chosen to legalize cannabis.”

    “It’s time for national policy to catch up with the states or at least get out of the way,” Titus said.

    The bill would also allow for interstate cannabis commerce, Shanita Penny, executive director of the Coalition for Cannabis Policy, Education and Regulation (CPEAR), said, and provide safe harbor for financial institutions, opening access to broader capital markets for marijuana companies.

    “We hit on all the typical business concerns” with the new STATES Act, Penny said, adding that if the bill was to become law it would make the SAFE Banking Act unnecessary.

    “This is that overarching federal framework that is going to ensure consistency across states for not only businesses … it’s an exciting bill for everybody involved,” Penny said.

    That said, the measure’s chances of getting through both chambers of Congress and all the way to the president’s desk are unclear. In past years, most pro-cannabis bills have died in the Senate, even if they made it through the House of Representatives. Penny also noted that so far there’s no Senate version of the STATES Act this year.

    “We don’t have a Senate companion bill. So before we can even talk about giving them an opportunity to move forward with this … we still have some work to do there,” she said. “While we certainly haven’t had any indications from Trump that there’s going to be action on this, what we have right now is an opportunity to reengage members… to make sure that when the administration gives us the green light, that we have a bill we can get passed and get onto his desk.”

    The post STATES Act reintroduced in Congress with bipartisan support appeared first on Green Market Report.

  • 4Front Ventures delays annual filings, can’t pay auditors

    4Front Ventures delays annual filings, can’t pay auditors

    4Front Ventures (CSE: FFNT) (OTCQB: FFNTF) said Wednesday it can’t meet its April 30 regulatory deadline to file its annual financial report because it can’t pay its auditors.

    The Phoenix-based company also applied for a management cease trade order that would temporarily restrict company leaders from trading its securities while it tries to fix its money problems.

    The delay comes as the company works to “resolve the issue and expects to be able to file the necessary reports upon completion of securing additional financing, restructuring its liabilities and continuing discussions with one of the company’s lessors,” according to a news release. Management stated that it expects to file within 60 days of restarting its audit.

    The delay follows a tough stretch for 4Front, which lost $6.4 million in the third quarter while watching its revenue slide. Third-quarter revenue dropped to $15.2 million, down from $20.1 million a year earlier and lower than the $18.7 million from the previous quarter.

    The company blamed “softness in our retail channel stemming from heightened competition” in both Illinois and Massachusetts markets for the revenue dip.

    Still, CEO Andrew Thut previously tried to sound positive, saying the company was making progress on scaling production in Illinois, growing wholesale in Massachusetts and seeing better results in Washington.

    “Despite the uncertainties surrounding federal cannabis reform, we’re optimistic, especially given signs that we may have unexpected advocates in the incoming administration,” Thut said at the time. “We’re confident entering Q4 and are ready to return to growth and sustainable positive cash flows from operations.”

    4Front also said at the time that it retained Canaccord Genuity to help with an internal reorganization, particularly regarding its financial position. The company also took out an $850,000 loan to finance ongoing operations.

    The company asked for relief under Canadian National Policy 12-203, which would block management from trading company securities until it files its financials. The Ontario Securities Commission hasn’t ruled on this request yet.

    If rejected, the commission might instead impose a broader order affecting all company securities.

    While the filings remain outstanding, 4Front promised to provide biweekly status updates and confirmed that insiders can’t trade company stock until the annual filings are submitted.

    The company has been pushing growth initiatives despite its financial crunch. During the third quarter, it continued building a massive 250,000-square-foot cultivation facility in Matteson, Illinois, planning to expand from 24,000 to 34,800 square feet of growing space. Its Massachusetts wholesale business showed some promise with a 56% increase in revenue to nearly $2 million for the quarter.

    As of September 2024, 4Front had $278 million in assets, with just $1.2 million in cash, against $326.5 million in liabilities, including nearly $69 million in debt.

    The company said there are no bankruptcy proceedings underway and “no material business developments” since filing its last quarterly report in December beyond what its already disclosed.

    The post 4Front Ventures delays annual filings, can’t pay auditors appeared first on Green Market Report.

  • Analysis: Cannabis Use Associated With Less Stress, Better Sleep Quality Among Military Veterans With PTSD

    Analysis: Cannabis Use Associated With Less Stress, Better Sleep Quality Among Military Veterans With PTSD

    A closeup of a military uniform with a cannabis leaf patch on the sleeve representing marijuana and veterans issuesA closeup of a military uniform with a cannabis leaf patch on the sleeve representing marijuana and veterans issues“While alcohol use appears to perpetuate a reinforcing cycle of stress and poor sleep, cannabis use may offer short-term stress relief and perceived sleep benefits,” investigators determined.

    The post Analysis: Cannabis Use Associated With Less Stress, Better Sleep Quality Among Military Veterans With PTSD appeared first on NORML.

  • Clinical Trial: Orally Administered Delta-8 THC Possesses Similar But Milder Effects Than Delta-9 THC

    Clinical Trial: Orally Administered Delta-8 THC Possesses Similar But Milder Effects Than Delta-9 THC

    Two cannabis leaves rest atop small squares of chocolate brownies arranged on a dark platterTwo cannabis leaves rest atop small squares of chocolate brownies arranged on a dark platterResearchers concluded, “The findings from the present study underscore the importance of establishing regulatory frameworks that address safety, labeling, and consumer education related to delta-8 THC products.”

    The post Clinical Trial: Orally Administered Delta-8 THC Possesses Similar But Milder Effects Than Delta-9 THC appeared first on NORML.

  • Study: CBD Reduces Chronic Pelvic Pain, Related Symptoms

    Study: CBD Reduces Chronic Pelvic Pain, Related Symptoms

    A person against a background of cannabis leaves wraps their arms around waist representing relief from pelvic painA person against a background of cannabis leaves wraps their arms around waist representing relief from pelvic painEighty-one percent of participants reported reduced pain following their use of CBD products.

    The post Study: CBD Reduces Chronic Pelvic Pain, Related Symptoms appeared first on NORML.